Beta Bionics (NASDAQ:BBNX) CFO Sells $87,023.20 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 5,104 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20. Following the sale, the chief financial officer owned 165,931 shares in the company, valued at $2,829,123.55. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total transaction of $84,184.36.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $16.76 on Friday. The stock has a market capitalization of $746.86 million, a P/E ratio of -11.10 and a beta of 3.02. The company has a 50 day moving average price of $12.45 and a 200 day moving average price of $15.13. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The company had revenue of $27.63 million for the quarter. On average, research analysts forecast that Beta Bionics, Inc. will post -2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Beta Bionics

Several hedge funds have recently added to or reduced their stakes in the stock. Summit Securities Group LLC purchased a new stake in shares of Beta Bionics during the 4th quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd grew its position in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. Strs Ohio acquired a new stake in Beta Bionics during the 1st quarter worth $29,000. Finally, Ameritas Investment Partners Inc. lifted its position in Beta Bionics by 139.1% in the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after acquiring an additional 1,863 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BBNX shares. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Truist Financial reduced their price target on Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. The Goldman Sachs Group decreased their price objective on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Stifel Nicolaus cut their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Leerink Partners reduced their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus target price of $19.70.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.